Literature DB >> 29599345

Significance of Perioperative Chemotherapy in Squamous Cell Carcinoma of the Upper and Lower Urinary Tract.

Tomoyuki Makino1, Kouji Izumi2, Ariunbold Natsagdorj1, Hiroaki Iwamoto1, Suguru Kadomoto1, Renato Naito1, Yoshifumi Kadono1, Atsushi Mizokami1.   

Abstract

BACKGROUND/AIM: To evaluate the clinicopathological characteristics and prognosis of squamous cell carcinoma (SCC) of the urinary tract (UT) urothelium, and investigate the utility of perioperative chemotherapy. PATIENTS AND METHODS: Thirty-three patients diagnosed with SCC in renal pelvis, ureter and bladder at the Kanazawa University between 2007 and 2017 were included in this retrospective study. Cancer-specific survival (CSS) rates according to cancer stage and neoadjuvant chemotherapy (NAC) were determined.
RESULTS: Among the entire cohort, two-year CSS rates were 100%, 75%, 47% and 0% in stages I, II, III and IV, respectively, with a significant correlation between CSS and cancer stage (p=0.0063). Sixteen patients underwent radical surgery, and seven patients received NAC; however, there were no significant differences in CSS rates among patients stratified by NAC (p=0.7043).
CONCLUSION: Worse cancer stage for SCC of UT urothelium was associated with worse prognosis. Given the poor efficacy of NAC in these patients, surgical treatment should be preferred. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Squamous cell carcinoma; bladder; renal pelvis; squamous differentiation; ureter

Mesh:

Year:  2018        PMID: 29599345     DOI: 10.21873/anticanres.12467

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  Squamous or Glandular Differentiation Predicts Poor Prognosis in pT1 Urothelial Carcinoma.

Authors:  Ryunosuke Nakagawa; Hiroaki Iwamoto; Tomoyuki Makino; Suguru Kadomoto; Hiroshi Yaegashi; Kazuyoshi Shigehara; Kouji Izumi; Yoshifumi Kadono; Atsushi Mizokami
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.